Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-33b* and miR-1825 microRNA therapeutics
- Development stage
- Preclinical
- Lead developer
- Heqet Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intracoronary Infusion, Endocardial Injection, Intramyocardial Injection, Intraventricular Injection Via Percutaneous Catheter
01
Overview
Heqet Therapeutics is developing a microRNA-based therapeutic program targeting miR-33b* (specifically the miR-33b-3p strand) and miR-1825 to promote cardiac regeneration. Founded as a spin-out from King's College London by Prof. Mauro Giacca, the company aims to treat myocardial infarction and prevent heart failure by stimulating the proliferation of surviving cardiomyocytes. These non-coding RNA modulators, likely microRNA mimics, are designed to induce heart muscle cell division, potentially enabling the repair of damaged tissue. The program is currently in the discovery phase. Heqet is collaborating with delivery platform partners, including 4basebio and Altamira Therapeutics, to optimize the delivery of these microRNA therapeutics to damaged heart tissue.
- Other names
- miR-33b*miR-1825miR1825miR 1825
02
Targets
Proto-oncogene serine/threonine-protein kinase Pim-1 mRNA 3'-untranslated region (PIM1 mRNA 3'-UTR)ATP-binding cassette transporter A1 mRNA 3'-untranslated region (ABCA1 mRNA 3'-UTR)NADH:Ubiquinone Oxidoreductase Subunit A10 mRNA 3'-untranslated regionCyclin D1 messenger RNA 3' untranslated regionCarnitine palmitoyltransferase 1A mRNA 3' untranslated regionHydroxyacyl-CoA dehydrogenase trifunctional effector complex subunit beta mRNA 3'-untranslated region5'-AMP-activated protein kinase catalytic subunit alpha mRNA 3'-untranslated regionCyclin-dependent kinase inhibitor 1A mRNA 3'-untranslated regionGlucose-6-phosphatase catalytic subunit mRNA 3'-untranslated regionMeis homeobox 2 (MEIS2) mRNA 3'-untranslated regionCarnitine O-octanoyltransferase mRNA 3'-untranslated regionPhosphoenolpyruvate carboxykinase 1 mRNA 3'-untranslated regionCyclin-dependent kinase 6 messenger RNA 3' untranslated region (CDK6 mRNA 3' UTR)Cyclin-dependent kinase inhibitor 2A messenger RNA 3'-untranslated regionSirtuin 6 mRNA 3'-untranslated region (SIRT6 mRNA 3'-UTR)Retinoblastoma 1 messenger RNA 3'-untranslated region (RB1 mRNA 3'-UTR)
Beyond the preview
Go deeper on miR-33b* and miR-1825 microRNA therapeutics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-33b* and miR-1825 microRNA therapeutics.